Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 17/20 | 0.52 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL114169 | 0.97 | TGFBR1 (0.49) | TGFBR1 | |
| SCHEMBL1612319 | 0.90 | HTR6 (0.54) | TGFBR1 | |
| SCHEMBL1612888 | 0.88 | TGFBR1 (0.49) | TGFBR1 | |
| SCHEMBL855334 | 0.87 | HTR6 (0.51) | TGFBR1 | |
| SCHEMBL6736311 | 0.83 | HTR6 (0.55) | TRIM24 | |
| Hydrochloric Acid SCHEMBL114792 | 0.83 | HTR6 (0.54) | TRIM24 | |
| SCHEMBL616959 | 0.81 | TRIM24 (0.42) | TGFBR1TRIM24 | |
| SCHEMBL6736320 | 0.80 | HTR6 (0.52) | TRIM24 | |
| Hydrochloric Acid SCHEMBL116025 | 0.80 | HTR6 (0.51) | TRIM24 | |
| SCHEMBL614832 | 0.79 | HTR6 (0.51) | TRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183237-B2 | Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | ABBOTT LABORATORIES (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2424844-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-20100292221-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2010-11-18 | — | — | US | disclosed |
| WO-2010125135-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292221-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR6, HTR1D, HTR4 | TGFBR1 1503/4885STS 414/4885TRIM24 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.